These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 24486428)

  • 41. The opiorphin gene (ProL1) and its homologues function in erectile physiology.
    Tong Y; Tar M; Melman A; Davies K
    BJU Int; 2008 Sep; 102(6):736-40. PubMed ID: 18410445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
    Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
    Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blockade of the renin-angiotensin system in heart failure in conscious dogs.
    Murakami M; Suzuki H; Naitoh M; Matsumoto A; Kageyama Y; Tsujimoto G; Saruta T
    J Hypertens; 1995 Dec; 13(12 Pt 1):1405-12. PubMed ID: 8866902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
    Kelly DJ; Cox AJ; Tolcos M; Cooper ME; Wilkinson-Berka JL; Gilbert RE
    Kidney Int; 2002 Jan; 61(1):31-9. PubMed ID: 11786082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
    Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].
    Winkler G; Jermendy G; Matos L
    Orv Hetil; 2003 Sep; 144(36):1763-8. PubMed ID: 14579673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of angiotensin II antagonism on the regression of kidney disease in the rat.
    Remuzzi A; Gagliardini E; Donadoni C; Fassi A; Sangalli F; Lepre MS; Remuzzi G; Benigni A
    Kidney Int; 2002 Sep; 62(3):885-94. PubMed ID: 12164870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat.
    Whaley-Connell AT; Chowdhury NA; Hayden MR; Stump CS; Habibi J; Wiedmeyer CE; Gallagher PE; Tallant EA; Cooper SA; Link CD; Ferrario C; Sowers JR
    Am J Physiol Renal Physiol; 2006 Dec; 291(6):F1308-14. PubMed ID: 16788142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats.
    Xu W; Song S; Huang Y; Gong Z
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1250-6. PubMed ID: 16872305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Valsartan abolishes most of the memory-improving effects of intracerebroventricular angiotensin II in rats.
    Braszko JJ
    Clin Exp Hypertens; 2005 Nov; 27(8):635-49. PubMed ID: 16303640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Opiorphin highly improves the specific binding and affinity of MERF and MEGY to rat brain opioid receptors.
    Tóth F; Tóth G; Benyhe S; Rougeot C; Wollemann M
    Regul Pept; 2012 Oct; 178(1-3):71-5. PubMed ID: 22771829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation.
    Siragy HM; Xue C; Abadir P; Carey RM
    Hypertension; 2005 Jan; 45(1):133-7. PubMed ID: 15534073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reversal of diabetic vasculopathy in a rat model of type 1 diabetes by opiorphin-related peptides.
    Calenda G; Tong Y; Kanika ND; Tar MT; Suadicani SO; Zhang X; Melman A; Rougeot C; Davies KP
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1353-9. PubMed ID: 21784987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Opiorphin levels in fluids of burning mouth syndrome patients: a case-control study.
    Boucher Y; Braud A; Dufour E; Agbo-Godeau S; Baaroun V; Descroix V; Guinnepain MT; Ungeheuer MN; Ottone C; Rougeot C
    Clin Oral Investig; 2017 Sep; 21(7):2157-2164. PubMed ID: 27834029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of opiorphin genes in prostate cancer growth and progression.
    Mukherjee A; Park A; Wang L; Davies KP
    Future Oncol; 2021 Jun; 17(17):2209-2223. PubMed ID: 33593085
    [No Abstract]   [Full Text] [Related]  

  • 57. Salivary opiorphin levels in anorexia nervosa: A case-control study.
    Paszynska E; Dmitrzak-Weglarz M; Roszak M; Boucher Y; Dutkiewicz A; Tyszkiewicz-Nwafor M; Gawriolek M; Otulakowska-Skrzynska J; Rzatowski S; Slopien A
    World J Biol Psychiatry; 2020 Mar; 21(3):212-219. PubMed ID: 30179071
    [No Abstract]   [Full Text] [Related]  

  • 58. A study of salivary opiorphin levels using different anesthetic drugs and techniques - A randomized controlled clinical study.
    Parida SK; Guruprasad T; Krishnakumar VB; Ravi RP
    J Stomatol Oral Maxillofac Surg; 2018 Jun; 119(3):169-171. PubMed ID: 29247820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Opiorphin: an endogenous human peptide with intriguing application in diverse range of pathologies.
    Tiwari C; Khan H; Grewal AK; Dhankhar S; Chauhan S; Dua K; Gupta G; Singh TG
    Inflammopharmacology; 2024 Oct; 32(5):3037-3056. PubMed ID: 39164607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. First-in-human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management.
    Moss LM; Berends CL; van Brummelen EMJ; Kamerling IMC; Klaassen ES; Bergmann K; Ville V; Juarez-Perez V; Benichou AC; Groeneveld GJ
    Br J Clin Pharmacol; 2022 Jan; 88(1):103-114. PubMed ID: 34046921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.